A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Phase 2
130
about 4.1 years
18+
15 sites in CT, FL, GA +8
About this study
Researchers are testing whether adding a treatment to chemotherapy and radiation therapy, followed by immunotherapy, can improve the response rate in people with advanced lung cancer. The trial will last about 1486 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Concurrent Chemo/Radiation Therapy (cCRT)
- 2.Receive Durvalumab
- 3.Take Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin
- +2 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
chemotherapy, durvalumab
infusion
Primary: Objective Response Rate (ORR) Using Independent Central Review (ICR) Assessment
Secondary: Disease Control Rate (DCR) Post-cCRT and Pre-cIT, Duration of Response (DoR), Number of Participants Reporting Laboratory Parameters, Physical Examination, Vital Signs Including Eastern Cooperative Oncology Group (ECOG) Performance Status Abnormalities, Number of Participants with Treatment-Emergent Adverse Event (TEAE) Related to Study Treatment, Objective Response Rate (ORR) Post-cCRT and Pre-cIT, Objective Response Rate (ORR) as Assessed by the Investigator, Progression Free Survival (PFS)
radiation
Oncology